Eli Lilly announced it will acquire psychedelic drugmaker AtaiBeckley for $2.8 billion in cash, marking a significant move into the emerging field of psychedelic-based mental health treatments [1]. The acquisition price of $6.75 per share represents a 26% premium over AtaiBeckley's previous closing price of $5.36 per share, with the potential for an additional $2.50 per share, or $1 billion, contingent on certain development and regulatory milestones being met [1].
The deal gives Lilly access to AtaiBeckley's lead drug, BPL-003, a DMT-based nasal spray currently in Phase 3 clinical trials for treatment-resistant depression. Initial results from these trials are expected in 2029. AtaiBeckley is also developing other psychedelic compounds for mental health conditions, including one related to MDMA (ecstasy) [1].
This acquisition is part of a broader trend, as the Trump administration has prioritized the development of psychedelic-based treatments for mental health conditions such as depression and post-traumatic stress disorder [1]. The deal also continues Lilly's recent pattern of large-scale acquisitions; prior to this announcement, the company had already committed over $10 billion up front and potentially up to $25 billion on eight acquisitions in 2026, focusing on later-stage and more expensive deals [1].
Following the announcement, AtaiBeckley shares surged more than 30% in premarket trading, reflecting strong market enthusiasm for the deal and the growing momentum behind psychedelic therapies in the pharmaceutical sector [1].
CONCLUSION
Eli Lilly's $2.8 billion acquisition of AtaiBeckley underscores the growing interest in psychedelic-based treatments for mental health. The deal, which sent AtaiBeckley shares soaring, positions Lilly at the forefront of this emerging therapeutic area and continues its strategy of high-value acquisitions.